<DOC>
	<DOC>NCT00607633</DOC>
	<brief_summary>The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the impact of the antihypertensive therapy with candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension..</brief_summary>
	<brief_title>Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy, Left Ventricular</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>essential hypertension left ventricular hypertrophy under candesartan treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>essential hypertension</keyword>
	<keyword>ARB</keyword>
	<keyword>left ventricular hypertrophy</keyword>
	<keyword>candesartan</keyword>
</DOC>